Prescient first in class cancer drug PTX-100 granted Orphan Drug status by the US FDA
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020,...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...
Investors have plenty of exciting updates to look forward as PTX advances clinical trials and...
Is the leukemia busting CAR-T cell therapy, championed by Aussie-listed Prescient, the holy grail of...
With around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR...
Prescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s attracting...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
The appointment gives PTX a world-leading development team in the race to find solutions for...
To stay up to date with Prescient Therapeutics news and events, please register your details.